Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy

By /

Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 million for Day One Biopharmaceuticals in 2025.

Scroll to Top